Canalevia ®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" ...

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs ...

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and ...

San Francisco, CA (July 7, 2015): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class ...

Jaguar Animal Health, which is developing an animal formulation of its parent's approved diarrhea treatment, raised $20 million by offering 2.86 million shares at $7, the low end of its originally ...

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ: JAGX) and Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), today announced an agreement (the “Agreement”) to ...

Company Prepares for New Prescription Drug Launch in First Half of 2016 for Dogs Suffering from Chemotherapy-Induced Diarrhea SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ: JAGX) ...

San Francisco, CA (November 21, 2014): Jaguar Animal Health, Inc. ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and ...

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today issued a reminder that company personnel are attending the Pet Connect ...